Zhang JJ, Ye XR, Liu XS, Zhang HL, Qiao Q. Impact of sodium-glucose cotransporter-2 inhibitors on pulmonary vascular cell function and arterial remodeling. World J Cardiol 2025; 17(1): 101491 [DOI: 10.4330/wjc.v17.i1.101491]
Corresponding Author of This Article
Qian Qiao, PhD, Professor, Chinese Academy Medical Sciences, Fuwai Yunnan Hospital, No. 528 Shahe North Road, Northwest New District, Wuhua District, Kunming 650000, Yunnan Province, China. qiaoqian1102@163.com
Research Domain of This Article
Respiratory System
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Cardiol. Jan 26, 2025; 17(1): 101491 Published online Jan 26, 2025. doi: 10.4330/wjc.v17.i1.101491
Impact of sodium-glucose cotransporter-2 inhibitors on pulmonary vascular cell function and arterial remodeling
Jing-Jing Zhang, Xue-Rui Ye, Xue-Song Liu, Hao-Ling Zhang, Qian Qiao
Jing-Jing Zhang, Xue-Rui Ye, Qian Qiao, Chinese Academy Medical Sciences, Fuwai Yunnan Hospital, Kunming 650000, Yunnan Province, China
Jing-Jing Zhang, Xue-Rui Ye, Qian Qiao, Kunming Medical University, Affiliated Cardiovascular Hospital of Kunming Medical University, Kunming 650000, Yunnan Province, China
Xue-Song Liu, Department of Biochemistry, Gansu University of Chinese Medicine, Lanzhou 730000, Gansu Province, China
Hao-Ling Zhang, Department of Biomedical Science, Advanced Medical and Dental Institute, University Sains Malaysia, Penang 13200, Malaysia
Co-corresponding authors: Hao-Ling Zhang and Qian Qiao.
Author contributions: Zhang JJ, Ye XR, Liu XS, Zhang HL, and Qiao Q completed the first draft of the paper; Zhang HL and Qiao Q had pivotal roles in the research design, guiding the research group and coordinating the collaborative efforts of all authors, providing detailed guidance, and revising the paper, they are the co-corresponding authors. All authors have read and approved the final manuscript.
Supported by Science and Technology Department of Yunnan Province - Kunming Medical University, Kunming Medical Joint Special Project - Surface Project, No. 202401AY070001-164; Yunnan Provincial Clinical Research Center Cardiovascular Diseases - New Technology Research for Development Project for Diagnosis and Treatment Cardiovascular Diseases, No. 202102AA310002; and the Key Technology Research and Device Development Project for Innovative Diagnosis and Treatment of Structural Heart Disease in the Southwest Plateau Region, No. 202302AA310045.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qian Qiao, PhD, Professor, Chinese Academy Medical Sciences, Fuwai Yunnan Hospital, No. 528 Shahe North Road, Northwest New District, Wuhua District, Kunming 650000, Yunnan Province, China. qiaoqian1102@163.com
Received: September 19, 2024 Revised: November 2, 2024 Accepted: December 17, 2024 Published online: January 26, 2025 Processing time: 124 Days and 1.4 Hours
Abstract
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors represent a cutting-edge class of oral antidiabetic therapeutics that operate through selective inhibition of glucose reabsorption in proximal renal tubules, consequently augmenting urinary glucose excretion and attenuating blood glucose levels. Extensive clinical investigations have demonstrated their profound cardiovascular efficacy. Parallel basic science research has elucidated the mechanistic pathways through which diverse SGLT-2 inhibitors beneficially modulate pulmonary vascular cells and arterial remodeling. Specifically, these inhibitors exhibit promising potential in enhancing pulmonary vascular endothelial cell function, suppressing pulmonary smooth muscle cell proliferation and migration, reversing pulmonary arterial remodeling, and maintaining hemodynamic equilibrium. This comprehensive review synthesizes current literature to delineate the mechanisms by which SGLT-2 inhibitors enhance pulmonary vascular cell function and reverse pulmonary remodeling, thereby offering novel therapeutic perspectives for pulmonary vascular diseases.
Core Tip: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are innovative antidiabetic agents that lower blood glucose by promoting its excretion via the kidneys. Beyond their glucose-lowering effects, SGLT2 inhibitors have demonstrated significant cardiovascular benefits in clinical trials. Emerging basic science research indicates that SGLT2 inhibitors also positively impact pulmonary vascular health. They enhance the function of pulmonary vascular endothelial cells, inhibit the proliferation and migration of pulmonary smooth muscle cells, reverse pulmonary arterial remodeling, and help maintain hemodynamic stability. This review consolidates current findings on the mechanisms by which SGLT2 inhibitors improve pulmonary vascular cell function and arterial remodeling, suggesting new therapeutic possibilities for pulmonary vascular diseases.
